UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 56

of 'Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer'

56
TI
Asymptomatic profound sinus bradycardia (heart rate≤45) in non-small cell lung cancer patients treated with crizotinib.
AU
Ou SH, Azada M, Dy J, Stiber JA
SO
J Thorac Oncol. 2011;6(12):2135.
 
Crizotinib, a dual MET/ALK inhibitor, is now in advanced clinical development for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). We have observed several patients who developed profound but asymptomatic sinus bradycardia (HR≤45) during the course of crizotinib treatment. Herein, we describe the clinical characteristics of three separate patients enrolled in the A8081001 trial (NCT00585195) who developed asymptomatic profound sinus bradycardia with their accompanying electrocardiogram tracings.
AD
Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California 92868-3298, USA. Ignatius.ou@uci.edu
PMID